Patents by Inventor Danny Ganame

Danny Ganame has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
    Patent number: 10005792
    Abstract: A compound of formula (1a), (1b) or (1c) wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d (if present) are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4a is selected from OH, —NH2, —C(?O)NH2, and —CH2OH; R4b is either H or Me; R5 is either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: June 26, 2018
    Assignee: CTXT PTY. LTD.
    Inventors: Ylva Elisabet Bergman, Romina Lessene, Danny Ganame, Richard Charles Foitzik, Benjamin Joseph Morrow, Michelle Ang Camerino, Scott Raymond Walker, H. Rachel Lagiakos, John Feutrill, Paul Anthony Stupple
  • AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS
    Publication number: 20170313713
    Abstract: A compound of formula (1a), (1b) or (1c) wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R1 and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d (if present) are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4a is selected from OH, —NH2, —C(?O)NH2, and —CH2OH; R4b is either H or Me; R5 is either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.
    Type: Application
    Filed: September 3, 2015
    Publication date: November 2, 2017
    Inventors: Ylva Elisabet Bergman, Romina Lessene, Danny Ganame, Richard Charles Foitzik, Benjamin Joseph Morrow, Michelle Ang Camerino, Scott Raymond Walker, H. Rachel Lagiakos, John Feutrill, Paul Anthony Stupple
  • FAK inhibitors
    Patent number: 9421205
    Abstract: A compound of the formula (I): where R1 or R2 is a cyclic amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: August 23, 2016
    Assignee: Cancer Therapeutics CRC PTY LTD.
    Inventors: Ian Peter Holmes, Yiva Bergman, Gillian Elizabeth Lunnis, Marica Nikac, Neil Choi, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene
  • VEGFR3 inhibitors
    Patent number: 9266864
    Abstract: This invention relates to compounds of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: February 23, 2016
    Assignee: CANCER THERAPEUTICS CRC PTY LIMITED
    Inventors: Richard Charles Foitzik, Neil Choi, Benjamin Joseph Morrow, Catherine Fae Hemley, Gillian Elizabeth Lunniss, Michelle Ang Camerino, Danny Ganame, Paul Anthony Stupple, Romina Lessene, Wilhelmus Johannes Antonius Kersten, Andrew John Harvey, Ian Peter Holmes
  • VEGFR3 inhibitors
    Patent number: 9238644
    Abstract: This invention relates to a compound of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: January 19, 2016
    Assignee: CANCER THERAPEUTICS CRC PTY LIMITED
    Inventors: Richard Charles Foitzik, Benjamin Joseph Morrow, Catherine Fae Hemley, Gillian Elizabeth Lunniss, Michelle Ang Camerino, Danny Ganame, Paul Anthony Stupple, Romina Lessene, Wilhelmus Johannes Antonius Kersten, Andrew John Harvey, Ian Peter Holmes
  • VEGFR3 INHIBITORS
    Publication number: 20160009686
    Abstract: This invention relates to a compound of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.
    Type: Application
    Filed: August 16, 2013
    Publication date: January 14, 2016
    Applicant: CANCER THERAPEUTICS CRC PTY LIMITED
    Inventors: Richard Charles Foitzik, Benjamin Joseph Morrow, Catherine Fae Hemley, Gillian Elizabeth Lunniss, Michelle Ang Camerino, Danny Ganame, Paul Anthony Stupple, Romina Lessene, Wilhelmus Johannes Antonius Kersten, Andrew John Harvey, Ian Peter Holmes
  • Selective FAK inhibitors
    Patent number: 9174946
    Abstract: A compound of the formula (I): where R1 or R2 is a cycle, amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: November 3, 2015
    Assignee: Cancer Therapeutics CRC Pty LTD
    Inventors: Ian Peter Holmes, Yiva Bergman, Gillian Elizabeth Lunniss, Marcia Nikac, Neil Choi, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene
  • Selective FAK inhibitors
    Patent number: 9120761
    Abstract: A compound of the formula (I): where R1 or R2 is a cyclc amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: September 1, 2015
    Assignee: Cancer Therapeutics CRC PTY LTD
    Inventors: Ian Peter Holmes, Ylva Bergman, Gillian Elizabeth Lunniss, Marica Nikac, Neil Chol, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene
  • FAK INHIBITORS
    Publication number: 20150231135
    Abstract: A compound of the formula (I): where R1 or R2 is a cyclic amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Application
    Filed: February 11, 2015
    Publication date: August 20, 2015
    Inventors: Ian Peter Holmes, Yiva Bergman, Gillian Elizabeth Lunnis, Marica Nikac, Neil Choi, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene
  • VEGFR3 INHIBITORS
    Publication number: 20150225377
    Abstract: This invention relates to compounds of the formula (I). The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphanglogenesis.
    Type: Application
    Filed: August 16, 2013
    Publication date: August 13, 2015
    Applicant: CANCER THERAPEUTICS CRC PTY LIMITED
    Inventors: Richard Charles Foitzik, Neil Choi, Benjamin Joseph Morrow, Catherine Fae Hemley, Gillian Elizabeth Lunniss, Michelle Ang Camerino, Danny Ganame, Paul Anthony Stupple, Romina Lessene, Wilhelmus Johannes Antonius Kersten, Andrew John Harvey, Ian Peter Holmes
  • FAK inhibitors
    Patent number: 9012461
    Abstract: A compound of the formula (I): where R1 or R2 is a cyclc amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: April 21, 2015
    Assignee: Cancer Therapeutics CRC Pty Ltd
    Inventors: Ian Peter Holmes, Ylva Bergman, Gillian Elizabeth Lunniss, Marica Nikac, Neil Choi, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene
  • VEGFR3 INHIBITORS
    Publication number: 20140080798
    Abstract: This invention relates to compounds of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.
    Type: Application
    Filed: August 16, 2013
    Publication date: March 20, 2014
    Applicant: CANCER THERAPEUTICS CRC PTY LIMITED
    Inventors: Richard Charles FOITZIK, Neil Choi, Benjamin Joseph Morrow, Catherine Fae Hemley, Gillian Elizabeth Lunniss, Michelle Ang Camerino, Danny Ganame, Paul Anthony Stupple, Romina Lessene, Wilhelmus Johannes Antonius Kersten, Andrew John Harvey, Ian Peter Holmes
  • VEGFR3 INHIBITORS
    Publication number: 20140073620
    Abstract: This invention relates to a compound of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.
    Type: Application
    Filed: August 16, 2013
    Publication date: March 13, 2014
    Applicant: CANCER THERAPEUTICS CRC PTY LIMITED
    Inventors: Richard Charles FOITZIK, Benjamin Joseph Morrow, Catherine Fae Hemley, Gillian Elizabeth Lunniss, Michelle Ang Camerino, Danny Ganame, Paul Anthony Stupple, Romina Lessene, Wilhelmus Johannes Antonius Kersten, Andrew John Harvey, Ian Peter Holmes
  • SELECTIVE FAK INHIBITORS
    Publication number: 20130324546
    Abstract: A compound of the formula (I): where R1 or R2 is a cycle, amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Application
    Filed: February 17, 2012
    Publication date: December 5, 2013
    Applicant: Cancer Therapeutics CRC Pty Limited
    Inventors: Ian Peter Holmes, Yiva Bergman, Gillian Elizabeth Lunniss, Marcia Nikac, Neil Choi, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene
  • FAK INHIBITORS
    Publication number: 20130324532
    Abstract: A compound of the formula (I): where R1 or R2 is a cyclc amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Application
    Filed: February 17, 2012
    Publication date: December 5, 2013
    Applicant: Cancer Therapeutics CRC Pty Limited
    Inventors: Ian Peter Holmes, Yiva Bergman, Gillian Elizabeth Lunniss, Marcia Nikac, Neil Choi, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene
  • SELECTIVE FAK INHIBITORS
    Publication number: 20130022594
    Abstract: A compound of the formula (I): where R1 or R2 is a cyclc amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Application
    Filed: July 6, 2012
    Publication date: January 24, 2013
    Applicant: Cancer Therapeutics CRC Pty Limited
    Inventors: Ian Peter Holmes, Ylva Bergman, Gillian Elizabeth Lunniss, Marica Nikac, Neil Chol, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene
  • FAK INHIBITORS
    Publication number: 20130017194
    Abstract: A compound of the formula (I): where R1 or R2 is a cyclc amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Application
    Filed: July 6, 2012
    Publication date: January 17, 2013
    Applicant: Cancer Therapeutics CRC Pty Limited
    Inventors: Ian Peter Holmes, Ylva Bergman, Gillian Elizabeth Lunniss, Marica Nikac, Neil Choi, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene